Kang Enbei acquires the property rights of new oral treatment drugs for 100 million yuan to enrich its large health product line

Full Data


Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?